Synthetic pDNA Vaccines for Specialized Environments
Legal Citation
Summary of the Inventive Concept
This inventive concept adapts synthetic pDNA vaccines against COVID-19 for specific, high-need environments, including high-security facilities, disaster relief, extreme weather conditions, areas with limited medical infrastructure, and high-altitude environments.
Background and Problem Solved
The original patent disclosed a synthetic pDNA vaccine against COVID-19, but it did not address the unique challenges and requirements of specific environments. This inventive concept solves the problem of inadequate vaccine administration and protection in these environments, ensuring effective vaccination and minimizing risks.
Detailed Description of the Inventive Concept
The inventive concept comprises systems, methods, and kits for administering synthetic pDNA vaccines against COVID-19 in specialized environments. These include secure storage units, controlled environments, portable vaccination units, remote monitoring systems, and supplemental oxygen provision. The inventive concept integrates the original vaccine design with tailored solutions for each environment, ensuring safe and effective vaccination.
Novelty and Inventive Step
The new claims introduce novel combinations of vaccine administration and environmental adaptations, providing a non-obvious solution to the problem of vaccine protection in specialized environments. The inventive concept's unique integration of vaccine design and environmental considerations sets it apart from the original patent.
Alternative Embodiments and Variations
Alternative embodiments may include varying vaccine formulations, adaptable storage and administration systems, and customized training programs for healthcare professionals. Variations may also include integrating the vaccine with existing infrastructure, such as incorporating the vaccine into existing emergency response systems or high-security facilities.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in industries such as biotechnology, healthcare, and emergency response. Target markets include high-security facilities, disaster relief organizations, and areas with limited medical infrastructure. The inventive concept also has potential applications in high-altitude environments, such as mountainous regions or aerospace industries.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K39/215 |
| A | A61 | A61K9/0019 |
| A | A61 | A61P31/14 |
| C | C07 | C07K14/005 |
| A | A61 | A61K2039/53 |
| A | A61 | A61K2039/54 |
| A | A61 | A61K2039/545 |
| C | C12 | C12N2770/20022 |
| C | C12 | C12N2770/20034 |
| C | C12 | C12N2770/20071 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Biotechnology and vaccine development, specifically synthetic plasmid DNA (pDNA) vaccines for infectious disease prevention, with expertise in molecular biology, immunology, and vaccine formulation techniques
Person of Ordinary Skill (PHOSITA) Profile
A researcher or engineer with advanced degrees in molecular biology or immunology, experienced in vaccine design, genetic engineering, and understanding of environmental adaptation strategies for biological materials
Obviousness Rationale
A person of ordinary skill would recognize that the source patent's pDNA vaccine technology naturally requires consideration of specialized environmental challenges during deployment. The PTD's variations represent predictable engineering solutions that address known limitations in vaccine distribution and administration across diverse contexts. These adaptations follow standard problem-solving approaches in biotechnology by integrating vaccine design with contextual delivery mechanisms.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,621 |
|---|---|
| Title | Synthetic pDNA vaccines against COVID-19 |
| Assignee(s) | Imam Abdulrahman Bin Faisal University |